#USA #Chicago #CDMO #ESTEVE #Regis Technologies

ESTEVE's Strategic Acquisition of Regis Technologies

In a significant move in the pharmaceutical industry, ESTEVE has successfully acquired Regis Technologies, a well-established Contract Development and Manufacturing Organization (CDMO) based in Chicago, USA. This acquisition marks an important step for ESTEVE in cementing its presence and capabilities within the US pharmaceutical market.

With over 65 years of experience, Regis Technologies offers a wide range of services essential for the drug development process, including process research, cGMP API manufacturing, and various chromatography products. Through this acquisition, ESTEVE aims to enhance its contract development and manufacturing solutions for small-molecule active pharmaceutical ingredients (APIs), effectively covering the entire drug development life cycle from pre-clinical stages to commercial manufacturing.

Joan Petit, Chief Industrial Operations Officer of ESTEVE and General Manager of ESTEVE CDMO (operating under the Esteve Química brand), shared insights on this acquisition, emphasizing that the integration of Regis Technologies not only adds capabilities but also expands their development and manufacturing capacity. "We are proud to announce the expansion of our team and the enhancement of our CDMO solutions for pharmaceutical innovators. This acquisition increases our workforce by approximately 70 skilled professionals," he stated.

Furthermore, ESTEVE CDMO is specialized in the production of high-quality small-molecule APIs and pharmaceutical intermediates. The company provides innovations such as Spray Drying and high-potency APIs (HPAPIs) manufacturing, catering to various clients in the pharmaceutical sector.

The US market holds strategic importance for ESTEVE. This acquisition plays a crucial role in fulfilling the company's mission of improving lives by enhancing CDMO capabilities and expanding integrated service offerings in this vital region. Staffan Schüberg, CEO of ESTEVE, emphasized the potential growth and expansion associated with this strategic acquisition, reflecting on the company’s long-standing commitment to improving people’s lives through enhanced pharmaceutical solutions.

Scott Aladeen, President and CEO of Regis Technologies, expressed his enthusiasm about joining ESTEVE, stating, "We are elated to be part of a company that shares our values. With over 90 years of experience, ESTEVE is family-owned and committed to delivering long-term value to its customers."

ESTEVE operates two primary business segments: the development and manufacturing of active ingredients for third parties (CDMO), supported by production facilities in Spain, Mexico, China, and now the United States. The second branch focuses on offering highly specialized medicines through affiliates in various countries including Germany, Spain, France, Italy, Portugal, the UK, and the USA.

Founded in 1929 and headquartered in Barcelona, ESTEVE is a global pharmaceutical company dedicated to providing specialized treatments that address significant unmet medical needs across various therapeutic areas. The company has a solid international presence with pharmaceutical affiliates across multiple regions, including Spain, Portugal, Italy, Germany, France, the UK, and the USA.

Along with its innovative pharmaceutical division, ESTEVE is committed to offering comprehensive CDMO services that specialize in the production of Active Pharmaceutical Ingredients through world-class facilities in several countries. Their core values remain deeply embedded in the organization, focused on people, transparency, and accountability.

In conclusion, the acquisition of Regis Technologies heralds a new chapter for ESTEVE, paving the way for increased capabilities and an expanded market presence in the US pharmaceutical landscape. With a dedication to quality and innovation, ESTEVE is poised to significantly impact the industry and further enhance its service offerings in active pharmaceutical development and manufacturing.